COVID vaccine: NTAGI holds meeting on Covovax inclusion as heterologous booster for adults on CoWin portal

Published On 2023-02-10 09:24 GMT   |   Update On 2024-02-13 19:24 GMT
Advertisement

New Delhi: National Technical Advisory Group on Immunisation conducted a meeting on February 8 regarding the inclusion of Covid-19 vaccine Covovax as a heterologous booster dose for adults on the CoWin portal to boost uptake of the doses, sources said on Thursday.

In the month January, the Serum Institute of India (SII) also wrote a letter to the Union Health Ministry seeking the inclusion of its Covid vaccine Covovax on the CoWIN portal.
On January 16, the Drugs Controller General of India (DCGI) approved market authorisation for the Serum Institute of India (SII) COVID jab Covovax as a heterologous booster dose.
Earlier, DCGI had approved Covovax for restricted use in emergency situations in adults on December 28, 2021, for ages between 12-17 on March 9, 2022, and also for children who come under 7- 11 years on June 28, 2022, subject to certain conditions.
Covovax is manufactured through technology transfer from Novavax. It has been approved by the European Medicines Agency for conditional marketing authorization. It was granted an emergency-use listing by the World Health Organization (WHO) on December 17, 2021.
Recently, Bharat Biotech's nasal Covid vaccine for adults above 18 years old had been launched by the Government of India and its batches were also released.
The vaccine is available in private hospitals.
iNCOVACC is the world's first Intranasal Vaccine to receive both Primary series and Heterologous booster approval. 

Read also: Serum Institute cervical cancer vaccine CERVAVAC to be available in market this month at Rs 2000 for two doses: Sources

COVID-19 disease is caused by a coronavirus called SARS-CoV-2.  It is predominantly a respiratory illness that can affect other organs. People with COVID-19 have had a wide range of symptoms reported, ranging from mild symptoms to severe illness. Symptoms may appear 2 to 14 days after exposure to the virus. Symptoms may include: fever or chills; cough; shortness of breath; fatigue; muscle or body aches; headache; new loss of taste or smell; sore throat; congestion or runny nose; nausea or vomiting; diarrhea.

Tags:    
Article Source : with inputs

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News